Corbus Pharmaceuticals receives Orphan Designation for lenabasum for the treatment of DM in EU

Corbus Pharmaceuticals announces that the European Commission has granted Orphan Designation in the European Union (EU) to lenabasum, its synthetic oral endocannabinoid-mimetic drug, for the treatment of dermatomyositis (DM). Read more >>